Actual results could differ materially from those currently a
nticipated due to a number of risks and uncertainties. Risk
s and uncertainties related to the acquisition of King by Pfizer that could cause results to differ from expectations include: uncertainties as to the timing of the merger; the possibility that a governmental entity may prohibit or delay the consummation of the merger; and the risk of shareholder litigation, including the disposition of currently pendin
...[+++]g litigation, in connection with the merger.